Di[3-deoxy-D-Manno-octulosonyl]-lipid A (amMonium salt)
Modify Date: 2024-01-12 12:09:05
![Di[3-deoxy-D-Manno-octulosonyl]-lipid A (amMonium salt) Structure](https://image.chemsrc.com/caspic/249/1246298-62-3.png)
Di[3-deoxy-D-Manno-octulosonyl]-lipid A (amMonium salt) structure
|
Common Name | Di[3-deoxy-D-Manno-octulosonyl]-lipid A (amMonium salt) | ||
|---|---|---|---|---|
| CAS Number | 1246298-62-3 | Molecular Weight | 2326.646 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C110H198N2Na4O39P2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Di[3-deoxy-D-Manno-octulosonyl]-lipid A (amMonium salt)Kdo2-Lipid A ammonium is a chemically defined lipopolysaccharide (LPS) with endotoxin activity equal to LPS. Kdo2-Lipid A ammonium is highly selective for TLR4. Kdo2-Lipid A ammonium stimulates the release of both TNF and PGE2[1]. |
| Name | Tetrasodium 3-deoxy-6-[(1R)-1,2-dihydroxyethyl]hex-2-ulopyranonosyl-(2->4)-3-deoxy-6-[(1R)-1,2-dihydroxyethyl]hex-2-ulopyranonosyl-(2->6)-2-deoxy-2-{[(3R)-3-(dodecanoyloxy)tetradecanoyl]amino}-4-O-(hydroxyphosphinato)-3-O-[(3R)-3-(tetradecanoyloxy)tetradecanoyl]hexopyranosyl-(1->6)-2-deoxy-1-O-(hydroxyphosphinato)-3-O-[(3R)-3-hydroxytetradecanoyl]-2-{[(3R)-3-hydroxytetradecanoyl]amino}hexopyranose |
|---|---|
| Synonym | More Synonyms |
| Description | Kdo2-Lipid A ammonium is a chemically defined lipopolysaccharide (LPS) with endotoxin activity equal to LPS. Kdo2-Lipid A ammonium is highly selective for TLR4. Kdo2-Lipid A ammonium stimulates the release of both TNF and PGE2[1]. |
|---|---|
| Related Catalog | |
| Target |
TLR4 |
| In Vitro | Kdo2-Lipid A (1 µM) stimulates the release of both TNF and PGE2 from the adult rat spinal astrocytes cell cultures[1]. RT-PCR[1] Cell Line: TNF and PGE2 Concentration: 1 µM Incubation Time: Result: Amounts of protein (mg) is 6.2 ± 0.6 ng/mL and 1.4 ± 0.3 ng/mL for TNF and PGE2. |
| In Vivo | KDO2-Lipid A (i.t.) activates toll-like receptor 4 (TLR4) in rats[1]. Animal Model: Rats (Male Holzman Sprague-Dawley, 300–400 g) [1] Dosage: 0.1 to 10 µg Administration: I.T.; 0.1-10 µg; prior and 15, 30, 60, 90 and 120 min after injection of Kdo2-Lipid A. Result: Intrathecal injection of 1 µg Kdo2-Lipid A induces allodynia, and the animals appeared to be sick after i.t. injection of Kdo2-Lipid A. |
| References |
| Molecular Formula | C110H198N2Na4O39P2 |
|---|---|
| Molecular Weight | 2326.646 |
| Exact Mass | 2325.263672 |
| Storage condition | 20°C |
| Tetrasodium 3-deoxy-6-[(1R)-1,2-dihydroxyethyl]hex-2-ulopyranonosyl-(2->4)-3-deoxy-6-[(1R)-1,2-dihydroxyethyl]hex-2-ulopyranonosyl-(2->6)-2-deoxy-2-{[(3R)-3-(dodecanoyloxy)tetradecanoyl]amino}-4-O-(hydroxyphosphinato)-3-O-[(3R)-3-(tetradecanoyloxy)tetradecanoyl]hexopyranosyl-(1->6)-2-deoxy-1-O-(hydroxyphosphinato)-3-O-[(3R)-3-hydroxytetradecanoyl]-2-{[(3R)-3-hydroxytetradecanoyl]amino}hexopyranose |
| Hexopyranose, O-3-deoxy-D-glycero-2-octulopyranonosyl-(2->4)-O-3-deoxy-D-glycero-2-octulopyranonosyl-(2->6)-O--2-deoxy-2-[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphonohexopyranosyl-(1->6)-2-deoxy-3-O-[(3R)-3-hydroxy-1-oxotetradecyl]-2-[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-, 1-(dihydrogen phosphate), sodium salt (1:4) |